Please assess the completion status of the following clinical trial:

Trial Title: FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* High risk prostate cancer:~  * clinical stage T3 (cT3) prostate cancer or~ * pre-treatment PSA \> 20 or~ * Gleason score\>8 on Trans-Rectal Ultrasound (TRUS) biopsy~* Score of \> 3 on the Vulnerable Elderly Scale or refuses standard radiotherapy + androgen deprivation therapy~* No evidence of extra-prostatic disease on screening bone scan and Computed Tomography (CT) scan (non-contrast CT used for CT simulation acceptable)~* Signed written and voluntary informed consent provided.~* Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures~* Age ≥ 18 years~Exclusion Criteria:~* Patients not meeting the eligibility criteria~* Prior pelvic radiotherapy or brachytherapy~* Use of anti-coagulation (low molecular weight heparin or Coumadin)~* History of inflammatory bowel disease, Crohn's disease, diverticulitis or collagen vascular disease (other than rheumatoid arthritis)~* Previous treatment for malignancy (other than basal or squamous cell skin cancer) within 3 years of prostate cancer diagnosis

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).